Novocure Limited (NASDAQ: NVCR) recently announced that its Tumor Treating Fields (TtFields) therapy for metastatic pancreatic cancer achieved positive top-line results in the phase 2 Panova-4 clinical trial.

The study achieved its primary endpoint, demonstrating encouraging signals of efficacy and a manageable safety profile. This groundbreaking progress brings new hope to patients suffering from this aggressive cancer. Tumor Treating Fields (TTFields) therapy is a local treatment method that uses electric fields of specific frequencies to interfere with the division of cancer cells. Pancreatic cancer has long been a major challenge in oncology due to its late diagnosis, limited treatment options, and poor prognosis. The successful results of the Panova-4 trial are expected to lay a solid foundation for subsequent pivotal clinical studies and further expand the application boundaries of TTFields therapy in the treatment of solid tumors.